BUFFALO, N.Y. (PRWEB) July 31, 2018
ZeptoMetrix™ Corporation (ZMC) announced today the release of 2 additional IVD/CE marked molecular quality controls to its expanding IVD/CE product inventory.
“We are pleased today to introduce two Group B Streptococcus molecular quality controls to our expanding IVD/CE QC offerings. ZeptoMetrix remains entirely committed to fully support and provide our diagnostics industry with as many precise and dependable, non-infectious tools as we can to assist with accurate and reliable QC”, explains Shawn Smith, President and CEO of ZeptoMetrix.
Dedicated to strengthening its IVD/CE core, ZeptoMetrix has utilized its patented NATtrol™ inactivation treatment to provide following GBS IVD/CE molecular quality controls:
Together, the routine and repetitive use of NATtrol™ External Run Controls and Range Verification Panels enables laboratories to verify test performance, track and monitor daily test variation, lot-to-lot test kit performance and individual operator performance to provide assistance identifying trends in laboratory results.